Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

By Vincent Wai-Sun Wong, G. Wong, P. Choi, A. Chan, Mia Li, H. Chan, A. Chim, Jun Yu, J. J. Sung, H. Chan. Gut, 2010

656 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/83474c55d2f15b6317cd0d194bd45d0fa39661f6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Hepatology

Citations in the corpus

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. (2015, background): “However, two small studies have recently challenged this dogma, suggesting that NAFL can evolve to NASH with advanced fibrosis, which would imply that it may not be an entirely benign condition [20,26].”
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD (2020, background): “0), from 57,103 (51,094-63,304) to 72,197 (64,602-79,915) for incidence and from 54,596 (48,457-60,847) to 66,875 (59,560-74,511) for deaths.”
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults (2011, methodology): “showing that four (18%) had simple steatosis and 13 (59%) had borderline NASH at month 36, whereas five (23%) developed NASH.(99) Among 17 patients with NASH at baseline, 10 (59%) continued to have NASH”
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “Fibrosis progression is possible among patients with simple steatosis or non-alcoholic steatohepatitis; approximately 25% to 37% of patients will have fibrosis progression in 3–5 years [226–228] [229].”
Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease (2017, neutral): “(Adams et al., 2005; Bhala et al., 2011; Matteoni et al., 1999; Singh et al., 2015; Wong et al., 2010) The presence of advanced fibrosis has consistently been identified as the most important predictor for liver-related events and complications in NAFLD, and therefore represents the most clinically…”
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes (2016, background): “(10,19) The variability of these rates is compounded by the technology used to establish the diagnosis of NAFLD and NASH.”
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up (2015, background): “Recently, fibrosis stage was suggested to predict liver-specific mortality more reliably than NAS(15); furthermore, the ability of NAS to predict progression of fibrosis has been shown to be poor.(16,17) The aim of the current study was to determine if long-term disease-specific mortality in NAFLD w”